Evaluating Claudin18.2 CAR-T Cell Therapy for Advanced Pancreatic and Gastric Cancer Assessing Safety and Effectiveness in Adults Aged 18 to 75

What this Trial Is About

Researchers are studying advanced pancreatic and gastric cancers, focusing on a protein called Claudin that is highly present in these cancer types. This research aims to test the safety and effectiveness of Claudin18.2 CAR-T cell therapy in patients with these advanced cancers, as current treatments need improvement. The study is led by Shenzhen University General Hospital and involves evaluating this new biological treatment. Participants in the study will receive Claudin18.2 CAR-T cells, which are designed to target cancer cells expressing the Claudin 18.2 protein. This treatment is given during the study period, and researchers will monitor its effects and safety. The study does not involve placebo or masking and includes patients with advanced, non-resectable cancers confirmed by pathology and specific criteria. During the trial, participants will be closely followed with careful monitoring of side effects from the infusion up to 30 days after treatment. Researchers will also assess tumor response and remission rates over up to two years. The study includes regular health assessments, blood tests, and tumor evaluations, with participants expected to have a survival outlook of more than three months. The total participation age range is 18 to 75 years old.

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T